Therapeutic responses to AZT + 3TC + EFV in advanced antiretroviral naive hiv type 1-infected ugandan patients

AIDS Research and Human Retroviruses

Volumn 18, Issue 16, 2002, Pages 1181-1187

  Kebba, Anthony ^a   Atwine, Diana ^a   Mwebaze, Raymond ^b   Kityo, Cissy ^a   Nakityo, Rose ^a   Peter, Mulenyi ^a  

^a JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^b Nsambya Hospital   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; INDINAVIR; LAMIVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; T LYMPHOCYTE; TREATMENT OUTCOME; UGANDA; VIRUS LOAD;

ADULT; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; OXAZINES; PATIENT COMPLIANCE; REVERSE TRANSCRIPTASE INHIBITORS; UGANDA; VIRAL LOAD; ZIDOVUDINE;

EID: 0036436105     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/08892220260387922     Document Type: Article

References (20)

1. Montaner JSG, Reiss P, Cooper D, et al.: A randomized, double blind trial comparing combinations of nevirapine, didanosine, and zidovudine in HIV-infected patients. The INCAS trial. JAMA 1998;279:930-937.
2. Scott LJ and Perry CM: Delavirdine: A review of its use in HIV infection. Drugs 2000;60:1411-1444.
3. Staszewki S: Update on Study 006 ± EFV + AZT + 3TC versus the current 'standard of care' IDV + AZT + 3TC. Int J Clin Pract Suppl 1999;103:10-15.
4. Bartlet JA, De Masi R, Quinn J, Moxham C, and Rousseau F: Overview of the effectiveness of triple combination therapy in antiretroviral naive HIV-1 infected adults. AIDS 2001;15:1369-1377.
5. Friedl AC, Ledergerber B, Flepp M, Hirschel B, Telenti A, Furrer H, Bucher HC, Bernasconi E, and Weber R: Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study. AIDS 2001;15:1793-1800.
6. Belle LL: Drug interactions and toxicities in patients with AIDS. In: The Medical Management of AIDS (Sande MA and Volberding PA, eds.), 5th Ed. W. B. Saunders, Philadelphia, PA, 1997, pp. 125-142.
7. Carr A, Samaras K, Burton S, et al.: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-F58.
8. Mulligan K, Grunfeld C, Tai VW, et al.: Hyperlipidaemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquired Immune Defic Syndr 2000;23:35-43.
9. Rabould J, Montaner JSG, Rae S, et al.: Patients with higher baseline pVL are less likely to have a virologic response in a metaanalysis of two trials of ZDV/ddi vs ZDV/ddi/NVP. 12th World AIDS Conference, Geneva, Switzerland, 1998, abstract 12361.
10. Palmer S, Alaeus A, Albert J, and Cox S: Drug susceptibility of subtypes A, B, C, D and E human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses 1998;14:157-162.
11. Hu DJ, Baggs J, Downing R, Pieniazek D, Dorn J, et al.: Predominance of HIV-1 subtype A and D infections in Uganda. Emerg Infect Dis 2000;6:609-615.
12. Weidle PJ, Kityo CM, Mugyenyi P, Downing R, Kebba A, Pieniazek D, Respess R, Hertogs K, De Vroey V, Dehertogh P, Bloor S, Larder B, and Lackritz E: Resistance to antiretroviral therapy among patients in Uganda. J Acquir Immune Defic Syndr 2001;26:495-500.
13. Jackson JB, Piwowar EM, Parsons J, Kataaha P, et al.: Detection of human immunodeficiency virus type 1 (HIV-1) DNA and RNA sequences in HIV-1 antibody positive blood donors in Uganda by the Roche AMPLICOR assay. J Clin Microbiol 1997;35:873-876.
14. Michael N, Herman S, Kwok S, Dreyer K, et al.: Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes. J Clin Microbiol 1999;37:2557-2563.
15. Takubwa J, Lule C, Mugyenyi P, Kebba A, and Tumukunde D: The effect of cost on anti-retroviral drug combinations in the management of HIV-AIDS at the Joint Clinical Research Center (JCRC) - Uganda. Fourth International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, 8-12 November, 1998, abstract P315.
16. Raboud JM, Rae S, and Montaner JS: Predicting HIV RNA virologic outcome at 52 weeks follow-up in antiretroviral clinical trials. The INCAS and AVATI study groups. J Acquir Immune Defic Syndr 2000;24:433-439.
17. Kim S, Hughes MD, Hammer SM, Jackson B J, DeGruttola V, and Katzenstein DA: Both serum HIV type 1 RNA levels and CD4+ lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4+ cells per cubic millimeter. AIDS Res Hum Retroviruses 2000;16:645-653.
18. Hanna GJ and D'Acquila RT: Antiretroviral drug resistance in HIV-1. Curr Infect Dis Rep 1999;1:289-297.
19. Kebba A, Mugyeni P, Mugerwa R, et al.: Comparison of double and triple therapy on CD4+ counts and viral load in a cohort of HIV-1 positive Ugandans. Fourth International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, 8-12 November, 1998, abstract P318.
20. Kaufmann GR, Block M, Zaunders JJ, Smith D, and Cooper DA: Long term immunological responses in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS 2000;14:959-969.